Virtual Library

Start Your Search

Yaokai Wen

Author of

  • +

    P1.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session) (ID 948)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.16-41 - The Role of Surgery in Pulmonary Large Cell Neuroendocrine Carcinoma: A Propensity-Score Matching Analysis of SEER Database (ID 12772)

      16:45 - 18:00  |  Author(s): Yaokai Wen

      • Abstract
      • Slides


      Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive subset of non-small-cell lung cancer with poor prognosis. Due to its rarity, the optimal therapy strategy for pulmonary LCNEC remains undefined. We aimed to evaluate the role of surgery for stage I-III LCNEC using the Surveillance, Epidemiology, and End Results (SEER) database.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Patients with stage I-III LCNEC were extracted from the SEER database (2004-2014). Propensity-score matching was performed to reduce the effect of potential confounders. Kaplan-Meier curves were constructed for overall survival (OS) and cancer-specific survival (CSS) for patient strata based on surgery use or nonuse. Multivariable Cox-regression was used to explore the efficacy of different treatment strategies.

      4c3880bb027f159e801041b1021e88e8 Result

      A total of 944 LCNEC patients were identified, of which 674 (71.4%) received surgery. Both OS and CSS of surgery use group were superior to surgery nonuse group in the whole cohort (HR=0.48, P<0.001 and HR=0.41, P<0.001, respectively). Among matched cohort, significantly greater benefits in OS and CSS (Figure 1) from surgery was observed in both stage I-II (HR=0.47, P=0.001 and HR=0.43 P<0.001, respectively) and stage III (HR=0.66, P=0.039 and HR=0.63, P=0.031, respectively). On multivariable analysis of surgical group, there was no significant difference in either OS or CSS between surgery alone and the addition of chemotherapy or (and) radiation for stage I-II patients, whereas favorable survival outcomes of surgery plus chemotherapy (OS: HR=0.26, P<0.001; CSS: HR=0.30, P=0.001) and surgery plus chemotherapy and radiation (OS: HR=0.33, P<0.001; CSS: HR=0.34, P=0.002) were significantly evident for stage III patients.

      figure-abstract 12772.jpg

      8eea62084ca7e541d918e823422bd82e Conclusion

      This is the largest study exploring the benefit of surgery for stage I-III pulmonary LCNEC. Regardless of stage, surgery showed remarkable survival benefits for LCNEC patients. It is suggested that surgery alone may be sufficient for stage I-II, whereas the multimodal combination of surgery and other therapies should be considered for stage III disease.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.